<DOC>
	<DOCNO>NCT00199849</DOCNO>
	<brief_summary>To estimate safety NY-ESO-1 Plasmid DNA ( pPJV7611 ) Cancer Vaccine give PMED patient tumor type know express NY-ESO-1 LAGE-1 use frequency , severity , duration treatment-related adverse effect endpoint .</brief_summary>
	<brief_title>NY-ESO-1 Plasmid DNA ( pPJV7611 ) Cancer Vaccine</brief_title>
	<detailed_description>Eligible patient tumor type know express NY-ESO-1 LAGE-1 antigen assign cohort . NY-ESO-1 Plasmid DNA ( pPJV7611 ) Cancer Vaccine administer PMED pressure 500 psi use XR-1 Powderject delivery device . The 4 microgram dosage NY-ESO-1 administer 4 X 1 microgram PMEDs close proximity . Similarly , 8 microgram dosage administer 8 X 1 microgram PMEDs . The third cohort patient receive 8 microgram dosage cluster dosage 4 dos ( day 1 , 3 , 5 , 8 ) 2 X 1 microgram PMEDs per day . Blood sample obtain baseline , 2 week vaccination , prior second third vaccination , 4 week third vaccination assessment clinical hematology , biochemistry measurement immunology response . Patients evaluate toxicity throughout study . DTH test perform NY-ESO-1 protein patient , NY-ESO-1b peptide HLA-A2+ patient NY-ESO-1 DP4 peptide HLA-DP4+ patient baseline 2-week visit follow first third vaccination . NY-ESO-1 and/or LAGE-1 specific antibody assess patient ELISA use recombinant NY-ESO-1 protein . NY-ESO-1 specific CD4+ CD8+ T cell assess patient tetramer and/or ELISPOT assay . Disease status assess baseline 4 week third vaccination patient measurable disease .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients eligible enrollment fulfill follow criterion : 1 . Histologically proven tumor type know express NYESO1 LAGE1 ( prostate cancer , breast cancer , bladder cancer , hepatocellular cancer , synovial sarcoma , leiomyosarcoma , head neck , lung cancer , esophageal , ovarian , neuroblastoma ) ; NYESO1 LAGE1 positive tumor determine reverse transcriptase polymerase chain reaction ( RTPCR ) analysis , preferably , immunohistochemistry expression LAGE1 RTPCR . 2 . Advanced disease decline , delay , fail complete standard therapy . 3 . Full recovery surgery . 4 . Expected survival least 6 month . 5 . Karnofsky performance scale &gt; 60 . 6 . Adequate bone marrow , kidney , liver immune function . 1 . Clinically significant heart disease ( NYHA Class III IV ) . 2 . Other serious illness , e.g. , serious infection require antibiotic bleed disorder , clinically significant liver renal insufficiency require treatment . 3 . Patients serious intercurrent illness , require hospitalization . 4 . Known HIV , Hepatitis B Hepatitis C positivity . 5 . History autoimmune disease ( e.g . SLE , scleroderma ) . Vitiligo exclusion criterion . 6 . Concomitant systemic treatment corticosteroid , antihistaminic drug nonsteroidal antiinflammatory drug . Specific COX2 inhibitor permit . Low dose aspirin permit . Topical inhalational steroid permit . 7 . Evidence skin disease ( e.g . psoriasis , eczema keloid formation ) propose administration site . 8 . Allergy gold ( include gold jewelry ) . 9 . History evidence chrysotherapy ( gold salt ) . 10 . Chemotherapy , radiation therapy , immunotherapy within 4 week prior first dose ( 6 week nitrosoureas ) . 11 . Other malignancy within 3 year prior entry study , except treat nonmelanoma skin cancer , cervical carcinoma situ incidental prostate cancer radical cystoprostatectomy specimen . 12 . Mental impairment , opinion investigator , may compromise ability give informed consent comply requirement study . 13 . Lack availability immunological clinical followup assessment . 14 . Participation clinical trial involve another investigational agent within 4 week prior first dose . 15 . Pregnancy breastfeed . 16 . Women childbearing potential : Refusal inability use effective mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>NY-ESO-1</keyword>
	<keyword>DNA</keyword>
</DOC>